Thank you to everyone who made the 2016 Course a success! 

COURSE OVERVIEW     |     AGENDA     |     ANNUAL SUPPORTERS

Course Overview

This was the 31st year of the course, “Medical and Surgical Aspects of Esophageal and Foregut Disorders: Pathophysiology and Treatment”. This year we are pleased to once again bring three outstanding leaders in the field of Esophageal Disease as our special guests to the Hawaii esophageal course.  Joining us will be Dr. C. Daniel Smith, our Surgical guest, and Drs. Stuart Spechler, and Dr. Ken Chang as our Medical guests. Together they will join our core faculty to discuss in detail the pathophysiology, diagnosis and therapy of diseases of the esophagus and foregut.  The course is specifically designed to be a classroom environment for a small group of interested physicians and allied health personnel. The course is particularly appreciated by gastroenterologists and gastrointestinal surgeons with interest in esophageal disorders and for those who have set up a swallowing center and function as a team to collaboratively approach esophageal problems.  The lectures are designed to encourage discussion on a broad variety of esophageal topics including both benign and malignant disorders.  

Dr. Daniel Smith has extensive expertise in minimally invasive surgery, as well as clinical outcomes following corrective therapies and operative management of GI diseases.  

Dr. Stuart Spechler, from UT Southwestern Medical Center, is widely renowned as an expert in diseases of the esophagus, with a special interest in gastroesophageal disease and Barrett’s esophagus. He has an active program of clinical research into the pathophysiology of Barrett’s esophagus. 

Dr. Ken Chang is Chief of Gastroenterology and Hepatology at the University of California, Irvine, and is also Director of the UC Irvine Health H.H. Chao Comprehensive Digestive Center and has received an endowed Chair in GI Endoscopic Oncology. He specializes in interventional endoscopy for esophageal and pancreatico-biliary disorders and is an expert in endoscopic ultrasound (EUS), EUS-guided fine needle aspiration and EUS-guided intervention. He is skilled in the endoscopic treatment of gastroesophageal reflux disease, endoscopic mucosal resection, laser-induced endomicroscopy, optical coherence tomography, radiofrequency and cryoablation therapy for Barrett¹s esophagus and esophageal cancer; as well as per-oral endoscopic myotomy (POEM) for Achalasia and various endoscopic bariatric procedures. His clinical research focuses on development of endoscopic modalities for cancer diagnosis, staging and therapy. He is the author of more than 200 publications and book chapters and has conducted numerous clinical trials on the development of new biologic agents against esophageal and pancreatic cancers. 

Highlights of this year’s course will be an interactive session on esophageal radiology and a number of debates on controversial topics in esophageal disease.  Also featured will be discussions on endotherapy and neoadjuvant therapy for esophageal cancer, novel diagnostic and therapeutic technology, and a special session on adopting novel technologies into a medical center. As in prior years  there will be “hands-on” break-out sessions involving high resolution motility, esophageal pH and pH + impedance monitoring, stents, novel diagnostic and therapeutic technologies, as well as a video demonstration room of the techniques for LINX, BÂRRX, EMR, EsophyX, endoscopic and laparoscopic myotomy for achalasia and esophagectomy. This portion of the course will expose the participants to each of these areas along with instruction, assistance and information exchange from the faculty. It promises to be a truly interesting, informative and enjoyable educational experience. 

We are pleased to again provide AMA PRA Category 1 credit ™ and self-assessment credits toward Part 2 of the ABS MOC Program.

 

Objectives

At the conclusion of this course, participants should be able to:

  1. Understand the  normal function and pathophysiology of the esophageal sphincters and esophageal body
  2. Describe and learn to interpret esophageal diagnostic studies including high-resolution manometry, pH and impedance testing, and novel technologies including optical coherence tomography and endomicroscopy
  3. Describe the diagnosis and management of GERD, Hiatal Hernia, Barrett’s Esophagus, and Esophageal adenocarcinoma
  4. Understand the traditional and novel therapies available for the endoscopic and surgical management of benign esophageal disease
  5. Discuss the staging for esophageal cancer and options for neoadjuvant and surgical therapy

Agenda

Thursday, February 4  
6:30 A.M.Continental Breakfast/Welcome/IntroductionsDr. S. DeMeester
Dr. Katz
7:00 A.M.Esophageal Symptoms: Pathogenesis and EvaluationDr. Katz
7:30 A.M.Discussion 
7:45 A.M.The LES in Health and DiseaseDr. S. DeMeester
8:15 A.M.Discussion 
8:30 A.M.Esophageal Mucosa in Health and DiseaseDr. Chandrasoma
9:00 A.M.Discussion 
9:15 A.M.Evaluation of Esophageal FunctionDr. Castell
9:45 A.M.Discussion  
10:00 A.M.Coffee Break and Case Discussions 
10:30 A.M.The History and Evolution of pH TestingDr. T. DeMeester
11:00 A.M.Discussion 
11:15 A.M.Esophageal Radiology: Superbowl of X-raysDr. Halls
12:30 P.M.Adjourn 
6:30 P.M. - 7:30 P.M.WELCOME RECEPTION at Makai Lawn 
Friday, February 5  
6:15 A.M.Early Riser's Video Session: Complex Hiatal Hernia RepariDr. Watson
6:30 A.M.Continental Breakfast/Case Presentation: GERDDr. Hussein
7:00 A.M.GERD: Definition and Scope of the ProblemDr. Spechler
7:20 A.M.Discussion 
7:30 A.M.Esophageal Eosinophils: Eosinophilic Esophagitis, GERD, Both?Dr. Katzka
7:50 A.M.Discussion 
8:00 A.M.PPIs: Best Dose, Best Drug and New Worries?Dr. Katz
8:20 A.M.Discussion 
8:30 A.M.Antireflux Surgery in 2016: Patient Selection and Maximizing OutcomesDr. Smith
8:50 A.M.Discussion 
9:00 A.M.Gastric Function and GERD: Implications for ManagementDr. Lipham
9:20 A.M.Discussion 
9:30 A.M.RYGB vs. Fundoplication for Primary or Redo OperationsDr. Smith
9:50 A.M.Discussion 
10:00 A.M.Coffee Break 
10:30 A.M.GERD and End-Stage Lung DiseaseDr. Hagen
11:00 A.M.Discussion 
11:15 A.M.Debate: Partial Response and Disease Progression:
Who, Why and How to Treat? (30 min. each)
Dr. T. DeMeester
Dr. Castell
12:15 P.M.Discussion 
12:45 P.M.Adjourn 
Saturday, February 6  
6:15 A.M.Early Riser's Video Session: LINX Magnetic Sphincter Augmentation Case
and Update on 5 Year Data
Dr. Lipham
Dr. Katz
6:30 A.M.The Challenge of Clinical Integration in US Health SystemsDr. Peters
7:00 A.M.Discussion 
7:15 A.M.New Diagnostic and Therapeutic TechnologyDr. Chang
7:45 A.M.Discussion 
8:00 A.M.Hands-On Breakfast Session: Sessions 1-5 (Sessions Will Be 30 Mins Each) 
 Five Simultaneous Sessions Will Be Presented At 8:00am, 8:30am, 9:00am, 9:30am, and 10:00am 
 9:30am, and 10:00am, /Simultaneous Sessions Include: 
 1. High Resolution Motility & Bravo pH TestingDr. Smith
Dr. Katzka
 2. Esophageal Function Testing Via MII And Impedance Reflux TestingDr. Castell
Dr. Katz
 3. Endoscopic Esophageal Diagnostic and Therapeutic ToolsDr. Watson
Dr. Chang
Dr. Peyre
 4. Enhanced Esophageal Biopsy and Tissue AnalysisDr. Hagen
Dr. Spechler
 5. Advanced Esophageal ImagingDr. Lipham
10:30 A.M.Coffee Break 
11:00 A.M.Endoscopic and Novel Therapies for GERD: Indications and EfficacyDr. Chang
11:20 A.M.Discussion 
11:30 A.M.DEBATE: GEJ, Cardiac Mucosa and IM (25 minutes each) 
 Clinicians ConceptsDr. Spechler
 Pathologists ConceptDr. Chandrasoma
12:20 P.M.Discussion 
12:45 P.M.Adjourn 
Sunday, February 7  
FREE DAY  
Monday, February 8  
6:15 A.M.Early Riser's Video Session: EMR and Advanced Endotherapy TechniquesDr. Chang
6:30 A.M.Continental Breakfast/Case Presentation: Barrett'sDr. Hibbard
7:00 A.M.Barrett's Esophagus: Scope of Problem and Risk Factors for ProgressionDr. Katzka
7:30 A.M.Discussion 
7:45 A.M.Doc, I got Barrett's. Now What?Dr. Peters
8:15 A.M.Discussion 
8:30 A.M.Endotherapy for Esophageal Cancer: Who, How and When is it Adequate?Dr. Chang
9:00 A.M.Discussion 
9:15 A.M.Pathology of ER Specimens: A Subjective AffairDr. S. DeMeester
9:45 A.M.Discussion 
10:00 A.M.Coffee Break and Case Discussion 
10:30 A.M.Reflux Management in BE Patients: PPI's, LINX or Fundoplication?Dr. Smith
10:50 A.M.Discussion 
11:00 A.M.Debate: Why is Esophageal Adenocarcinoma Increasing in the USA? (25 minutes each) 
 It's Obesity and More GERDDr. Spechler
 It's PPI's and How We Medically Treat GERDDr. S. DeMeester
11:50 A.M.Discussion 
12:00 P.M.Case Presentations and Panel Discussion 
12:45 P.M.Adjourn 
6:30 P.M.COURSE DINNER at Aloha Garden Ballroom/Pavilion 
Tuesday, February 9  
6:15 A.M.Early Riser's Video Session: Endoscopic Surgery, POEM and BeyondDr. Dunst
6:30 A.M.Continental Breakfast/ Case Presentation: Smooth Muscle TumorDr. Ghatak
7:00 A.M.Endoscopic Techniques to Find Early CancersDr. Katzka
7:20 A.M.Discussion 
7:30 A.M.Los Angeles, Prague and Paris: Worthwhile Systems or Just Great Cities?Dr. Katz
7:50 A.M.Discussion 
8:00 A.M.Are Endoscopists Giving Patients their Money's Worth?
Standards for reporting an EGD
Dr. S. DeMeester
8:20 A.M.Discussion 
8:30 A.M.GIST vs Leiomyoma: How to Tell and Does It Matter?Dr. Chandrasoma
8:50 A.M.Discussion 
9:00 A.M.Management of Smooth Muscle Lesions in the Esophagus and StomachDr. Watson
9:20 A.M.Discussion 
9:30 A.M.Chemoradiotherapy without Surgery: Valid Option for Resectable Disease?Dr. Peyre
9:50 A.M.Discussion 
10:00 A.M.Coffee Break and Case Discussions 
10:30 A.M.DEBATE: Adenocarcinoma of the GEJ debate (25 minutes each) 
 Gastrectomy with Roux is BestDr. Lipham
 Esophagectomy is BestDr. Watson
11:20 A.M.Discussion 
11:30 A.M.DEBATE: Who Gets Neoadjuvant Therapy? (25 minutes each) 
 Everyone Other than Intramucosal Tumor As Staging is UnreliableDr. Peyre
 Selective Based on StagingDr. Hagen
12:20 P.M.Discussion 
12:30 P.M.Wrap Up- Summary 
12:45 P.M.Adjourn 

Annual Course Supporters

2016

We Gratefully Acknowledge Educational Grants from the Following Companies:

We Gratefully Acknowledge In-Kind Support Product Donation from the Following Companies:

We Gratefully Acknowledge Exhibit Support from the Following Companies: